Journal of Pediatric Hematology/Oncology · 2018 · 11 citations · 14 references
MedicinePharmacologyPharmacotherapyChemotherapyPediatric Clinical PharmacologyPediatric PharmacotherapyAdverse Effects Of ChemotherapyNausea ControlNausea ManagementPediatric ChemotherapyVomiting ControlVomiting ManagementChemotherapy-induced Nausea PreventionChemotherapy-induced Vomiting PreventionChemotherapy-related ToxicityDelayed Chemotherapy-induced NauseaDelayed Chemotherapy-induced VomitingHigh-emetogenic Chemotherapy ProphylaxisNausea And Vomiting ControlTelephone Follow-up Calls
A neurokinin-1 (NK1) receptor antagonist is recommended with a 5-HT3 receptor antagonist and dexamethasone for prevention of chemotherapy-induced nausea and vomiting (CINV) in adult patients receiving highly emetogenic chemotherapy. Data for fosaprepitant use in pediatric patients is lacking. A retrospective chart review was conducted using an electronic medical record to characterize the use of fosaprepitant in patients aged 10 months to 18 years at a single institution from August 2015 to January 2017. Thirty-nine patients received fosaprepitant 4 mg/kg (maximum, 150 mg) for prevention of CINV, and 35 were included in the analysis. Ten patients 5 years of age or older who received fosaprepitant after October 2016 were eligible for a follow-up phone call to assess control of delayed CINV. Complete control of emesis was observed in 89% of patients during the acute phase, 63% during the delayed phase, and 60% overall. Overall incidence of nausea as documented in the medical record was 43%. Among the 10 patients who completed follow-up phone calls, 30% experienced emesis and 50% experienced nausea after discharge. Fosaprepitant may be safe and effective in the prevention of CINV in pediatric patients as young as 10 months of age.
14
Paul J. Hesketh, Steven M. Grunberg, Richard J. Gralla et al. · Journal of Clinical Oncology · 2003 · 776 citations
Fausto Roila, Alex Molassiotis, Jørn Herrstedt et al. · Annals of Oncology · 2016 · 580 citations · Full text
Steven M. Grunberg, Daniel T. T. Chua, Anish Maru et al. · Journal of Clinical Oncology · 2011 · 221 citations · Full text
Ronald de Wit, Jørn Herrstedt, Bernardo L. Rapoport et al. · Journal of Clinical Oncology · 2003 · 148 citations
Medicine, Oncology, Pharmacology +17